Ulrich Keilholz

Ulrich Keilholz's AcademicInfluence.com Rankings

Ulrich Keilholz

Engineering

#5656

World Rank

#6919

Historical Rank

Biomedical Engineering

#450

World Rank

#459

Historical Rank

engineering Degrees

Ulrich Keilholz

Philosophy

#7815

World Rank

#11073

Historical Rank

Logic

#4851

World Rank

#6181

Historical Rank

philosophy Degrees

Download Badge

Engineering
Philosophy

Why Is Ulrich Keilholz Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ulrich Keilholz's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study (2019) (871)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects (2011) (519)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial (2008) (474)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (338)
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. (2015) (335)
Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy (2002) (323)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (312)
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial (2005) (291)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. (2009) (289)
A clinical development paradigm for cancer vaccines and related biologics. (2007) (274)
CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. (2002) (260)
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. (2012) (241)
Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors (2017) (235)
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). (2011) (210)
Circulating tumor cells: the 'leukemic phase' of solid cancers. (2006) (210)
Natural T cell immunity against cancer. (2003) (202)
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. (1998) (199)
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. (2007) (190)
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. (1997) (187)
Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity (2004) (186)
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. (2013) (186)
Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. (2012) (185)
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. (2003) (181)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. (2005) (167)
Hematogenous spread of malignant melanoma cells in different stages of disease. (1993) (167)
Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas (1997) (166)
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients (2011) (162)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. (2011) (158)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (2019) (157)
Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. (2000) (152)
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. (2000) (147)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (144)
Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. (1997) (143)
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019) (140)
Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. (2013) (140)
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). (2009) (137)
A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. (1997) (135)
Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma (2000) (134)
Quantitative real‐time RT‐PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers (2004) (133)
The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer (2009) (132)
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. (2011) (132)
EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. (2008) (132)
A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. (1995) (131)
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. (2002) (129)
Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. (2006) (128)
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. (2007) (128)
Serum interleukin‐8 (IL‐8) is elevated in patients with metastatic melanoma and correlates with tumour load (1995) (127)
Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. (1998) (124)
Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study. (2019) (119)
Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ‐ELISPOT assay (1997) (115)
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. (2006) (115)
The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). (2011) (110)
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. (2009) (105)
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. (2011) (100)
Immunologic Analysis of a Phase I/II Study of Vaccination with MAGE-3 Protein Combined with the AS02B Adjuvant in Patients with MAGE-3-Positive Tumors (2004) (100)
Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-Time Reverse Transcriptase-Polymerase Chain Reaction (2004) (99)
Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins (1997) (99)
Short German guidelines: Malignant melanoma (2008) (99)
Wilms' tumour gene 1 (WT1) in human neoplasia (2005) (91)
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. (2008) (89)
Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. (2017) (88)
Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer (2007) (87)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Functional CCR9 expression is associated with small intestinal metastasis. (2004) (86)
Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment (2011) (86)
Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib (2009) (84)
Interferon‐α and interleukin‐2 in the treatment of metastatic melanoma. Comparison of two phase II trials (1993) (84)
Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. (1989) (83)
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. (2016) (82)
Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases (2008) (82)
ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee. (2020) (79)
Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma (2007) (79)
Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides (2003) (78)
Expression of the stem cell markers nestin and CD133 on circulating melanoma cells. (2011) (77)
Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031) (2008) (77)
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer (2016) (77)
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. (2006) (77)
Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma (2007) (76)
Flow cytometric determination of intracellular or secreted IFNγ for the quantification of antigen reactive T cells (2001) (76)
Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. (2016) (75)
Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (2007) (74)
Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. (2014) (73)
Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors (1999) (73)
Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. (2008) (73)
Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. (1997) (73)
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. (2006) (73)
Quantification of Tumor-Specific T Lymphocytes With the ELISPOT Assay (2000) (71)
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits (2008) (71)
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. (2021) (71)
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial (2018) (70)
Application of the IFN-γ ELISPOT assay to quantify T cell responses against proteins (2001) (69)
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) (2014) (69)
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. (2008) (69)
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (68)
Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment (2009) (67)
Immune Monitoring of T-Cell Responses in Cancer Vaccine Development (2006) (67)
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. (2016) (66)
Bone marrow contains melanoma-reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD8+ memory T cells. (2003) (66)
Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to Immunotherapy (1994) (64)
Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. (2018) (63)
Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients (2001) (62)
Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1 (2006) (60)
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. (2011) (60)
High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma (2000) (59)
Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. (2016) (59)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial (2019) (58)
Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. (2012) (58)
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). (2015) (58)
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part (2011) (57)
Lipopolysaccharide Effectively Up‐Regulates B7‐1 (CD80) Expression and Costimulatory Function of Human Monocytes (1995) (56)
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. (2002) (56)
Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial (2019) (53)
Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. (2004) (53)
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin (2002) (52)
A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option (2015) (52)
The combinatorial complexity of cancer precision medicine (2014) (52)
Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. (2007) (52)
Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine (2010) (51)
Role of TGF-β in melanoma. (2011) (51)
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures (2019) (50)
Expression of chemokine receptors on circulating tumor cells in patients with solid tumors (2012) (50)
Molecular staging in stage II and III melanoma patients and its effect on long-term survival. (2005) (50)
Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. (2005) (49)
Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer (2008) (48)
Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome (2010) (48)
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. (2021) (48)
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). (2009) (48)
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma. (2015) (47)
Cancer stem cell characteristics of circulating tumor cells (2014) (45)
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma (2005) (45)
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2. (2006) (45)
CMV‐specific central memory T cells reside in bone marrow (2007) (45)
Expression of Wilms’ tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants (2004) (44)
Short German guidelines: Merkel cell carcinoma (2008) (44)
Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. (1994) (44)
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia (2010) (44)
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. (2015) (43)
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II (2018) (43)
Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at Charité. (2009) (42)
Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack (2014) (41)
Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial (2005) (41)
Differences in T‐cell immunity toward tumor‐associated antigens in colorectal cancer and breast cancer patients (2003) (40)
The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin αvβ3 expression (2001) (40)
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2019) (40)
Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie (2013) (40)
Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma (2007) (39)
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). (2005) (39)
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. (1999) (38)
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial† (2016) (38)
ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee. (2020) (38)
Prognostic Relevance of Circulating Tumor Cells in Metastatic Uveal Melanoma (2011) (37)
Long‐term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders (1989) (37)
Application of the IFN-gamma ELISPOT assay to quantify T cell responses against proteins. (2001) (37)
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? (2013) (37)
The Emerging Role of Cytokines in the Treatment of Advanced Melanoma (2000) (37)
4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma (2007) (36)
Regional administration of lymphokine‐activated killer cells can be superior to intravenous application (1992) (36)
Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment (2002) (35)
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma (2005) (35)
Rational peptide-based tumour vaccine development and T cell monitoring. (2003) (35)
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. (1997) (35)
A LARGE OPEN-LABEL, NON-COMPARATIVE, PHASE III STUDY OF THE MULTI-TARGETED KINASE INHIBITOR SORAFENIB IN EUROPEAN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (2008) (35)
Possible regulation of Wilms’ tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA‐1 in human acute myeloid leukaemias (2003) (35)
Immunological monitoring of cancer vaccine therapy (2004) (35)
Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. (1996) (34)
Endocrine function and bone metabolism 5 years after autologous bone marrow/blood‐derived progenitor cell transplantation (1997) (33)
A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results. (2018) (33)
T cell responses against tumor associated antigens and prognosis in colorectal cancer patients (2005) (33)
Differential expression and functional behaviour of the αv and β3 integrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthritis and osteoarthritis in vitro (1997) (33)
Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. (1997) (32)
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype (2012) (32)
Fractionated Irradiation Can Induce Functionally Relevant Multidrug Resistance Gene and Protein Expression in Human Tumor Cell Lines (2005) (31)
Ifosfamide/liposomal daunorubicin is a well tolerated and active first‐line chemotherapy regimen in advanced soft tissue sarcoma (2005) (31)
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (31)
Detection of clonally rearranged T-cell-receptor gamma chain genes from T-cell malignancies and acute inflammatory rheumatic disease using PCR amplification, PAGE, and automated analysis (1997) (31)
A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma (2004) (30)
Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway (2015) (30)
Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. (1994) (30)
Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. (2016) (30)
Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR (2001) (29)
Expression of the stem cell marker nestin in peripheral blood of patients with melanoma (2010) (29)
Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. (1997) (29)
Detection of mutations in circulating cell‐free DNA in relation to disease stage in colorectal cancer (2019) (29)
Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. (2007) (29)
Kurzleitlinie – Malignes Melanom der Haut (2006) (29)
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma (2017) (29)
EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial (2007) (28)
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck (2015) (28)
Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives (2016) (28)
A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. (1996) (28)
Differential expression and release of LFA‐3 and ICAM‐1 in human melanoma cell lines (1993) (28)
Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome (2009) (27)
Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. (1990) (27)
[Brief guidelines: malignant melanoma of the skin]. (2006) (27)
Comparison of Treatment Recommendations by Molecular Tumor Boards Worldwide. (2018) (27)
Vitiligo-like lesions following immunotherapy with IFNα and IL-2 in melanoma patients (1994) (27)
Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix (2016) (27)
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine (2010) (26)
Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations (2008) (26)
CD 8 T-cell responses to Wilms tumor gene product WT 1 and proteinase 3 in patients with acute myeloid leukemia (2002) (26)
Benefits and Risks of Skin Cancer Screening (2014) (26)
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics (2014) (26)
Ocular melanoma: what's new? (2012) (26)
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors (2014) (26)
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee (2020) (26)
Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. (2017) (26)
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy (2008) (25)
The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions (2019) (25)
“Wilms Tumor Protein 1” (WT1) Peptide Vaccination-induced Complete Remission in a Patient With Acute Myeloid Leukemia Is Accompanied by the Emergence of a Predominant T-cell Clone Both in Blood and Bone Marrow (2011) (25)
Diagnostic PCR in melanoma, methods and quality assurance. Epalinges, Switzerland, 26/27 January 1996 (1996) (24)
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the α and β chains (p55 and p75) (1992) (24)
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. (2011) (24)
New prognostic factors in melanoma: mRNA tumour markers. (1998) (24)
Mutational load and mutational patterns in relation to age in head and neck cancer (2016) (24)
A sensitive proliferation assay to determine the specific T cell response against HLA-A2.1-binding peptides. (1996) (24)
The pattern of metastasis of human melanoma to the central nervous system is not influenced by integrin alpha(v)beta(3) expression. (2001) (23)
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee (2020) (23)
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. (2001) (23)
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study (2005) (23)
Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides (2002) (23)
Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. (1993) (23)
Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951) (2000) (23)
Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy (1996) (23)
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) (23)
Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats (2004) (23)
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. (2008) (22)
Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. (2001) (22)
PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab‐docetaxel (2015) (21)
Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination (2010) (20)
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors. (2019) (20)
Intracellular Cytokine Staining (2005) (20)
Innovations and Challenges in Melanoma: Summary Statement from the First Cambridge Conference (2006) (19)
Support of a molecular tumour board by an evidence-based decision management system for precision oncology. (2020) (19)
Treatment of melanoma. (2008) (19)
Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer (2017) (19)
Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease. (2002) (19)
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial (2020) (19)
Polymerase chain reaction detection of circulating tumour cells (1997) (18)
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients (2012) (18)
Biochemotherapy for advanced melanoma. (2002) (18)
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. (2004) (18)
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. (1996) (18)
Comparative Analysis of Public Knowledge Bases for Precision Oncology. (2019) (18)
p16, HPV, and Cetuximab: What Is the Evidence? (2017) (18)
Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplati (2002) (18)
Prevalence and associated survival of high-risk HPV-related adenoid cystic carcinoma of the salivary glands. (2016) (18)
TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). (2020) (18)
Nested quantitative real time PCR for detection of occult tumor cells. (2001) (18)
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. (2004) (18)
HLA class I alleles and responsiveness of melanoma to immunotherapy with interferonalpha (IFN-α) and interleukin-2 (IL-2) (1994) (18)
Annotation and initial evaluation of a large annotated German oncological corpus (2021) (18)
Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. (2020) (17)
The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. (2000) (17)
Induction of tyrosinase‐reactive T cells by treatment with dacarbazine, cisplatin, interferon‐alpha ± interleukin‐2 in patients with metastatic melanoma (1999) (17)
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors (2013) (17)
Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. (2011) (16)
Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. (2003) (16)
Development and validation of a nomogram to predict recurrence and melanoma‐specific mortality in patients with negative sentinel lymph nodes (2018) (16)
From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity (2018) (16)
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). (2014) (16)
An intron 9 containing splice variant of PAX2 (2009) (16)
B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720 (2015) (16)
Polymerase chain reaction detection of circulating tumour cells. EORTC Melanoma Cooperative Group, Immunotherapy Subgroup. (1997) (16)
Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants (2008) (16)
Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial. (2018) (16)
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. (2006) (16)
Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. (2004) (15)
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis (2020) (15)
Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. (2009) (15)
Detection of tumour cells in the bloodstream of patients with uveal melanoma: influence of surgical manipulation on the dissemination of tumour cells in the bloodstream (2015) (15)
The Interdisciplinary Management of Brain Metastases. (2016) (15)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non–Small Cell Lung Cancer (2017) (15)
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance. (2015) (15)
Docetaxel, cisplatin (TP), and radiation with or without cetuximab in advanced larynx carcinoma (DeLOS II trial). (2010) (14)
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients (2005) (14)
Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients (2016) (14)
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma. (1995) (13)
BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). (2016) (13)
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer (2020) (13)
Regulation of interleukin-8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor-alpha and interferon-gamma. (1996) (13)
Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities (2021) (13)
1135OPhase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN) (2017) (13)
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. (2016) (13)
Spinal paraparesis due to leukemic meningitis in early-stage chronic lymphocytic leukemia (2005) (13)
Systemic Immune Tuning in Renal Cell Carcinoma: Favorable Prognostic Impact of TGF-&bgr;1 mRNA Expression in Peripheral Blood Mononuclear Cells (2011) (13)
Targeted Therapy of Head and Neck Cancer (2016) (12)
STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM). (2017) (12)
Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study. (2013) (12)
Cancer patients' expectations when undergoing extensive molecular diagnostics—A qualitative study (2019) (12)
LDH is a prognostic factor in stage IV melanoma patients (pts) but is a predictive factor only for bcl2 antisense treatment efficacy: Re-analysis of GM301 and EORTC18951 randomized trials (2007) (12)
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). (2019) (12)
Long‐term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin‐2 in poor risk melanoma patients (1998) (12)
Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. (1994) (12)
Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). (2011) (12)
Minimal Residual Disease in Melanoma (2001) (12)
Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides (2006) (11)
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). (1992) (11)
Next-generation sequencing: hype and hope for development of personalized radiation therapy? (2015) (11)
Peripheral blood mononuclear cell collection from patients undergoing adoptive immunotherapy or peripheral blood‐derived stem cell transplantation and from healthy donors (1991) (11)
Multiplexed quantification of four neuroblastoma DNA targets in a single droplet digital PCR reaction. (2020) (11)
LBA29_PRAFATINIB VERSUS METHOTREXATE (MTX) AS SECOND-LINE TREATMENT FOR PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) WHO PROGRESSED AFTER PLATINUM-BASED THERAPY: PRIMARY EFFICACY RESULTS OF LUX-HEAD & NECK 1, A PHASE III TRIAL (2014) (11)
Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients (2010) (11)
Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. (2012) (11)
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial (2021) (10)
Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. (1986) (10)
Phase I Dose Escalation Study of Carboplatin to a Fixed Dose of Irinotecan as First-Line Treatment of Small Cell Lung Cancer (2004) (10)
A Multicentre Phase II Study of Docetaxel plus Cisplatin for the Treatment of Advanced Gastric Cancer (2007) (10)
Analysis of cancer-related mutations in extracellular vesicles RNA by Droplet Digital™ PCR. (2020) (10)
Identification of truncated chemokine receptor 7 in human colorectal cancer unable to localize to the cell surface and unreactive to external ligands (2008) (10)
UV‐induced N-ras mutations are T‐cell targets in human melanoma (1997) (10)
Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells (2007) (10)
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC (2019) (9)
Internal control for quality assurance of diagnostic RT-PCR. (1998) (9)
Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. (2003) (9)
Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas (2019) (9)
Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial. (2009) (9)
Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial (2018) (9)
Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy (2015) (9)
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial (2021) (9)
appendix 2: Cutaneous melanoma (2): eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Melanoma). (2016) (9)
Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients. (2015) (8)
Effects of human papillomavirus (HPV) and other potential risk factors on survival in patients with oropharyngeal cancer. (2011) (8)
Stem cell marker nestin expression in peripheral blood of patients with melanoma. (2010) (8)
First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. (2017) (8)
Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients. (2017) (8)
[Resection of solitary liver metastases of malignant melanoma]. (1995) (8)
Identification of an Immunogenic HLA-A*0201-binding T-cell Epitope of the Transcription Factor PAX2 (2009) (8)
Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay. (2010) (8)
CIRCULATING TUMOR CELLS AS TUMOR BIOMARKERS IN MELANOMA : DETECTION METHODS AND CLINICAL RELEVANCE (2014) (8)
What can we learn from phase II adjuvant trials in melanoma? (2000) (8)
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. (2020) (8)
[Current role for induction chemotherapy in head and neck tumors]. (2008) (8)
Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC). (2016) (8)
Variant information systems for precision oncology (2018) (7)
Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients (2017) (7)
Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer (2008) (7)
Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study (2007) (7)
Rheumatic disease following immunotherapy. (1993) (7)
The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer (2016) (7)
The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer. (2002) (7)
Clinical and immune responses of WT1-peptide vaccination in patients with acute myeloid leukemia. (2006) (7)
VIST - a Variant-Information Search Tool for precision oncology (2019) (7)
Temsirolimus Is Active in Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Failing Platinum-Based Chemotherapy and Cetuximab: Efficacy and Toxicity Data from the Phase II Temhead Study (2012) (7)
NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. (2021) (7)
Addition of dacarbazine or cisplatin to interferon‐α/interleukin‐2 in metastatic melanoma: toxicity and immunological effects (1995) (7)
A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. (2020) (7)
Information, communication, and cancer patients’ trust in the physician: what challenges do we have to face in an era of precision cancer medicine? (2020) (6)
A monoclonal melanoma-specific T-cell population phenotypically indistinguishable from CD3+ LGL-leukemia. (2003) (6)
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. (1995) (6)
Large open-label, non-comparative, clinical experience trial of the multi-targeted kinase inhibitor sorafenib in European patients with advanced RCC (2008) (6)
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial. (2012) (6)
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo (2020) (6)
Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. (1994) (6)
A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer (2014) (6)
Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108. (2014) (6)
Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma. (2001) (6)
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) (2013) (5)
Induction chemotherapy (IC) followed by radiotherapy (RT) vs. cetuximab plus IC and R in resectable advanced laryngeal/hypopharyngeal cancer (LHSCC) – final results from the randomized DeLOS-II trial (2018) (5)
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany (2021) (5)
Long term presence of a single predominant tyrosinase‐specific T‐cell clone associated with disease control in a patient with metastatic melanoma (2010) (5)
Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma (2004) (5)
Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC (2020) (5)
Intermittent Low-Dose IFN Gamma Treatment for Metastatic Renal Cell Carcinoma: Analysis of Factors Predicting Clinical Response and Long-Term Survival (1995) (5)
Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment. (2011) (5)
Chemoimmunotherapy of melanoma. It time for phase III trials? (1995) (5)
1234PA RANDOMIZED, DOUBLE-BLIND, PHASE 2 TRIAL OF VELIPARIB (ABT-888) WITH CARBOPLATIN AND PACLITAXEL IN PREVIOUSLY UNTREATED METASTATIC OR ADVANCED NON-SMALL CELL LUNG CANCER. (2014) (5)
Surface expression of gpA33 is dependent on culture density and cell-cycle phase and is regulated by intracellular traffic rather than gene transcription. (2008) (5)
Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial (2020) (5)
Social network, autonomy, and adherence correlates of future time perspective in patients with head and neck cancer (2018) (5)
Should cT2 esophageal cancer get neoadjuvant treatment before surgery? (2017) (5)
95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT (2010) (5)
First-line treatment patterns for recurrent and/or metastatic head and neck cancer (R/M HNC) in Europe. (2010) (5)
IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation (2022) (4)
Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients (2017) (4)
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers. (2022) (4)
Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. (2006) (4)
Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: A two cohort phase II study. (2006) (4)
Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer. (2011) (4)
An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting Pegylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN). (2009) (4)
A randomized trial of IFNα/IL-2 with or without CDDP in advanced melanoma: An EORTC melanoma cooperative group trial (1996) (4)
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer (2004) (4)
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models (2021) (4)
987OCETUXIMAB (C), FLUOROURACIL (F) AND CISPLATIN (P) ALONE OR WITH DOCETAXEL (D) FOR RECURRENT/METASTATIC (RM) HEAD AND NECK CANCER (HNSCC). FINAL ANALYSIS OF AIO TRIAL # 1108 - CEFCID. (2014) (4)
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors (2022) (4)
Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: A randomized phase II trial (2005) (4)
Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasound-guided fine needle aspiration cytology. (2011) (4)
Monitoring of circulating tumor cells in a patient with synchronous metastatic melanoma and colon carcinoma. (2010) (4)
Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems (2022) (4)
RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence (2021) (3)
Association of an APOBEC mutational signature, mutational load, and BRCAness with inflammation and PD-L1 expression in HNSCC. (2017) (3)
Associations between the EGFR status as well as KRAS mutations and clinical outcome in colorectal cancer (CRC) patients (pts) treated with erlotinib monotherapy in 2nd or 3rd line—A study of the Arbeitsgemeinschaft Internistische (2008) (3)
Antigen-specific cancer vaccines. (2007) (3)
Disappearing cancer (2006) (3)
Automated Real-Time Tumor Pharmacokinetic Profiling in 3D Models: A Novel Approach for Personalized Medicine (2020) (3)
Effect of vaccination of leukemia patients with a MHC class I peptide of Wilms tumor gene 1 (WT1) peptide with unspecific T helper stimulation on WT1-specific IgM responses and on IgG responses (2008) (3)
Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature (2019) (3)
Somatic genome alterations in relation to age in lung adenocarcinoma (2019) (3)
Clinical and Immunological Activity of WT1 Peptide Vaccination in Patients with Acute Myeloid Leukemia and Myelodysplasia: Results of a Phase II Trial. (2006) (3)
[Choroid melanoma. Adjuvant therapy in high risk patients and new therapy approaches in the metastatic stage]. (2002) (3)
PO-091: TPExtreme randomized trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-P-C in recurrent/metastatic HNSCC (2015) (3)
Biochemotherapy of melanoma. (2003) (3)
Relationship between soluble tumor necrosis factor (TNF) receptors and TNFα during immunotherapy with interleukin-2 and/or interferon α (1994) (3)
Somatic genome alterations in relation to age in lung squamous cell carcinoma (2018) (3)
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis. (2020) (3)
Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial. (2018) (3)
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. (2019) (3)
Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients. (2005) (3)
Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos). (2010) (3)
RESPONSIVENESS TO IL-2 BASED IMMUNOTHER- APY DEPENDS ON HLA-TYPE OF THE PATIENT (1992) (3)
Abstract 2978: Generation of drug response data from 57 new patient-derived colon cancer xenografts and 3D cell cultures for systematic correlation with tumor biology within the OncoTrack* project (2014) (3)
Garbe C, Hauschild A, Volkenandt M et al.Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393-399 (2008) (3)
Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study. (2018) (3)
8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN) (2009) (3)
Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study. (2016) (3)
Perfusion of liver metastases with LAK cells: 352 (1993) (3)
Expression of stem cell markers in circulating melanoma cells. (2009) (2)
Analysis of chemokine receptor expression on circulating tumor cells (CTC) in patients with solid tumors. (2011) (2)
614 First-in-man Dose Escalation and Pharmacokinetic Study of CAP7.1, a Novel Etoposide Prodrug in Adults with Heavily Pretreated Solid Tumors (2012) (2)
Abstract 919: Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium (2019) (2)
Kurzleitlinie: Malignes Melanom der Haut (2006) (2)
Phase II trial of vaccination with WT1 peptide, GM-CSF, and KLH in patients with acute myeloid leukemia and myelodysplasia: Final immunological, molecular, and clinical results (2007) (2)
Unresolved questions regarding the promise of the TPEx regimen - Authors' reply. (2021) (2)
Treatment of Metastatic Melanoma with Interferon-α and Interleukin-2: Significant Improvement with a New Dosing Schedule (1992) (2)
[Side effects and complications of intra-arterial tumor therapy--experiences with 577 interventions]. (1995) (2)
The PARP inhibitor olaparib (AZD2281) as potent radiosensitizer of head and neck cancer cells. (2012) (2)
142 ELDERLY PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)SUCCESSFULLY TREATED (2009) (2)
Phase II study of liposomal daunorubicin and ifosfamide (IDx) as first line chemotherapy in soft tissue sarcoma. (2004) (2)
Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC. (2017) (2)
Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients (2005) (2)
Erratum: Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas. Int. J. Cancer, 71, 320–324 (1997) (1997) (2)
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC. (2015) (2)
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study (2021) (2)
Induction of multidrug resistance on mRNA and on protein level by fractionated irradiation (2004) (2)
Combined modality therapy of metastatic melanoma: the ʼHeidelberg approachʼ (1993) (2)
Immune Self-tuning in Renal Cell Carcinoma (2010) (2)
Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data (2021) (2)
254 A SUBANALYSIS OF PATIENTS WITH AND WITHOUT PRIOR NEPHRECTOMY IN A LARGE OPEN-LABEL, NON-COMPARATIVE PHASE 3 EUROPEAN ADVANCED RENAL CELL CARCINOMA (RCC) SORAFENIB STUDY (EU-ARCCS) (2009) (2)
Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis (2022) (2)
Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers. (2016) (2)
Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis (2022) (2)
Phase-II-study of a 24-h infusion with 5-fluorouracil (5-FU) and simultaneous sodium-folinic acid in the first-line-treatment of advanced colorectal cancer: interim analysis (1999) (2)
PERFUSION OF LIVER METASTASES WITH LAK CELLS (1993) (2)
Phase I/II trial of gemcitabine plus treosulfan (GeT) in stage IV uveal melanoma and carcinomas. (2004) (1)
Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD). (2013) (1)
Stimulating an immune response through bavituximab in a phase III lung cancer study. (2014) (1)
Induction of multidrug resistance on mRNA and on protein level by fractionated irradiation. (2004) (1)
1142P Treatment of metastatic uveal melanoma (mUM) through genomic profiling (2020) (1)
Can routine register data be used to identify vulnerable lung cancer patients of suboptimal care in a German comprehensive cancer centre? (2021) (1)
ACTIVATION OF MONONUCLEAR PHAGOCYTES BY IMMUNOTHERAPY WITH HIGH DOSE INTERLEUKIN-2: COMPARISON WITH AN INTERFERON-γ PROTOCOL (1993) (1)
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. (2006) (1)
Comparison of Standard to Split-Dose TPF Induction Chemotherapy followed by Bio-radiation for LASCC of the Head and Neck: Results of the ICRAT randomized Phase II Study. (2015) (1)
PHASE I TRIAL OF ADJUVANT VACCINATION WITH TYROSINASE PEPTIDES AND GM-CSF IN MELANOMA (1999) (1)
Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC. (2019) (1)
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
Expression of chemokine receptors on circulating tumor cells in patients with solid tumors (2012) (1)
Efficacy of a structured workflow for the interpretation of comprehensive genomic analysis data in clinical routine. (2018) (1)
Association of circulating tumor cells are associated with lymph node metastasis in squamous cell carcinoma of the head and neck region (SCCHN). (2010) (1)
Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer? (2009) (1)
[Repetitive immuno-embolization of inoperative liver metastases of renal cell carcinoma. Method characterization and preliminary results]. (1996) (1)
patients with acute myelogenous leukemia Disease-free survival after autologous bone marrow transplantation in (2011) (1)
Abstract 3149: Enumeration and mutational profiling of CTCs and comparison to ctDNA and colorectal cancer liver metastases (2016) (1)
Risk stratification of sentinel node positive melanoma patients defines surgical management and adjuvant therapy treatment considerations (2019) (1)
Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial (2019) (1)
A randomized trial of IFNα and IL-2 ± cisplatinum in advanced melanoma — a preliminary analysis (1995) (1)
Immunotherapy comes of age: overview of the 21st Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer (2007) (1)
WT1) peptide vaccination in patients with AML and MDS A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (2009) (1)
What is the Role of Biological Response Modifiers in the Treatment of Melanoma (2007) (1)
HPV and Other Risk Factors: Oropharyngeal Tumor Survival (2011) (1)
Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1-expressing solid tumors as compared to patients with AML/MDS. (2011) (1)
Treatment of Metastatic Melanoma with Interferon-α and High-Dose Interleukin-21 (1994) (1)
Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas. (2016) (1)
Addition of Histamine to IL-2 Treatment Augments T1 Cell-Funktion in Melanoma Patients In Vivo: Results from a Randomized Clinical Trial of IL-2 with or without Histamine (MP 104) (2004) (1)
Association of a STK11/KEAP1-mutation gene expression signature in lung adenocarcinoma with immune desertion in squamous cell carcinomas and mediation by NFE2L2 deregulation. (2020) (1)
143PA comparison of treatment recommendations by molecular tumor boards worldwide (2017) (1)
Comprehensive targeted next-generation sequencing to reveal limited clonal evolution after concurrent chemoradiation in patients with squamous cell carcinoma of the head and neck. (2017) (1)
Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival. (2010) (1)
Lymphoma Cells Are Highly Sensitive to Cytotoxic T-Cell-Killing Despite Presence of Multiple Resistance Mechanisms (2004) (1)
Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards (2022) (1)
PCR based detection of melanoma cells: Molecular staging? (1997) (1)
Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone) (2007) (1)
Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma (1999) (1)
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics (2014) (1)
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study. (2022) (1)
25 Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB–III (2004) (1)
Addition of histamine to IL-2 treatment augments T1 cell-function in melanoma patients in vivo: results from a randomized clinical trial of IL-2 with or without histamine (MP 104) (2004) (1)
OC-005: Afatinib versus methotrexate in recurrent/metastatic HNSCC after platinum therapy: LUX-head and neck (2015) (1)
MHC-Molecules and immunotherapy of malignant melanoma: 288 (1993) (1)
[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma]. (2017) (1)
Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts Short title: GENETIC ANOMALIES IN MSCs OF MDS/AML PATIENTS (2011) (1)
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. (2010) (1)
Employing head and neck cancer patient derived xenografts to inform clinical trial design: Results from combining regorafenib with everolimus. (2015) (1)
The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (2018) (1)
RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence (2021) (1)
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy. (2012) (1)
Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms. (2018) (1)
IL-2 treatment decreases frequencies of IL-10-producing regulatory T cells type 1 (Tr1) (2006) (1)
OC-021: Biomarker results from BERIL-1: buparlisib and paclitaxel in patients with platinum-pretreated SCCHN (2017) (0)
Pretreatment prognostic parameters for response to immunotherapy with IFNαL-2 in metastatic melanoma (MM) (1993) (0)
INV 29 Treatment of advanced disease or adjuvant treatment (2007) (0)
Primary Extracellular Matrix Enables Long-Term Cultivation of Human Tumor Oral Mucosa Models (2020) (0)
Substanzprofile: Zytostatika, Hormone, Zytokine1 (2009) (0)
Addition of CDDP or DTIC to immunotherapy in melanoma (1993) (0)
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. (2013) (0)
SP-036: Immunity and immune toxicity: clinical management of immune checkpoint inhibition (2017) (0)
Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors. (2011) (0)
First results of Expression V Study, a survey by the North-Eastern-German Society of Gynaecological Oncology (NOGGO), assessing the therapy expectations of breast and ovarian cancer patients with different ethnicity in Germany. (2015) (0)
Abstract 5059: Breast cancer patient-derived xenograft models for pre- and co-clinical investigation of immune based therapies (2020) (0)
Abstract 2018: A pipeline within the OncoTrack project for generating Patient-tumor-derived 3D cell cultures (PT3DC) and their application for individualized, targeted drug sensitivity assays (2014) (0)
Immunotherapy in non-renal carcinomas (2004) (0)
Changing landscape of clinical cancer trials in Germany (2019) (0)
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo (2021) (0)
Combined modality therapy of metastatic melanoma: the 'Heidelberg approach' 182 (1993) (0)
Surgical resection of residual disease following IL-2 based immunotherapy: 287 (1993) (0)
A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36) (2022) (0)
Band 24, Heft 2, April 2001 (2001) (0)
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy. (2012) (0)
26 Vaccine approaches in high-risk patient populations (2004) (0)
Differential expression and release of ICAM-1 and LFA-3 in melanoma cells: 277 (1993) (0)
Prognostic Parameters in Melanoma for Response to Immunotherapy (1993) (0)
Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity (2004) (0)
Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma. (2006) (0)
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. (2010) (0)
Precision oncology for the treatment of salivary gland tumors. (2019) (0)
Regression of choroidal melanoma after primary chemotherapy (2010) (0)
Adjuvant Tyrosinase Peptide Vaccination in Combination with GM-CSF and KLH for Induction of Specific T Cell Responses in Melanoma (2004) (0)
Postoperative detection of circulating EGFR transcripts as a surrogate marker for circulating tumor cells to predict tumor recurrence after adjuvant radio(chemo)therapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). (2013) (0)
1024 EGFR single nucleotid polymorphism R521K is a predictor for the occurrence of skin rash (2009) (0)
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]. (2022) (0)
Phase II Study of Intermittent Low-Dose IFN-gamma in Metastatic Renal Cell Cancer (1993) (0)
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial (2021) (0)
The Interleukin-2 Receptor (CD25 and p75) in Human Monocytes and Macrophages (1992) (0)
3 Identification of plasma proteins predictive for second-line therapy response in metastatic renal cell carcinoma (2015) (0)
Abstract 5013: Rapid generation of phenomic and functional profiles of patient-derived 3D cell culture models for identification of treatment vulnerabilities of breast cancer: Early results of the EFRE-PoP project (2018) (0)
Association of methylation of homologous repair genes with expression of immune checkpoints in squamous cell carcinoma of head and neck, lung and cervix. (2016) (0)
Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy (2015) (0)
Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1) (2023) (0)
INHIBITION OF INTERLEUKIN-8 RELEASE BY INTERFERON-γ IN MALIGNANT MELANOMA (1993) (0)
Abstract 1714: The role of Hedgehog signaling in the regulation of human colon cancer stem cells (2016) (0)
Expression of gplOO in Melanoma Métastasés Resected Before or After Treatment with IFNa and IL-2 (2017) (0)
Abstract No. 184: Transarterial Chemoembolization (TACE) of Liver Metastases from Uveal Melanoma: Evaluation of Efficacy and LDH as a Prognostic Factor (2009) (0)
Abstract 4099: Novel patient-derived 3D (PD3D) cell models and matched patient-derived xenografts (PDX) from peritoneal metastasis of colorectal cancer for drug testing and biomarker analysis (2018) (0)
224 Docetaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancer: results of a multicentre phase II study (2003) (0)
A proliferation assay to determine specific T-cell immunity using HLA I-binding peptides (1995) (0)
Multiepitope/Helper Protein Vaccination in Melanoma: Clinical Activity Correlates With Preexisting T Cell Responses and Normal LDH (2005) (0)
Regulation of interleukin‐8 mRNA expression and protein secretion in a melanoma cell line by tumour necrosis factor‐α and interferon‐γ (1996) (0)
847P Precision oncology for resistant acral, mucosal and cutaneous melanomas: A prospective broad high throughput genomics feasibility study (2022) (0)
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial (2018) (0)
VITILIGO FOLLOWING IMMUNOTHERAPY WITH IFNα AND IL-2 IN MELANOMA PATIENTS - CLINICAL EVIDENCE FOR MELANOCYTE-LINEAGE SPECIFIC ANTIGENS AS TUMOR TARGET EPITOPES (1994) (0)
Identification of epitopes of cancer testis antigen cyclin A1 for targeted T-cell therapy of acute myeloid leukemia (AML) and solid tumors. (2017) (0)
3091 Characterization of advanced NSCLC patients with prolonged benefit after veliparib plus carboplatin/paclitaxel: Phase 2 results (2015) (0)
A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma and cardiac risk factors. (2004) (0)
Next-generation sequencing: hype and hope for development of personalized radiation therapy? (2015) (0)
14 Next generation sequencing (NGS) approach to identify genetic alterations in head and neck squamous cell carcinoma (2015) (0)
Collecting wisdom: Creating an evidence framework for personalized cancer therapy. (2016) (0)
Clinical prognostic factors for distant metastases and survival in patients with primary uveal melanoma: A 10-year follow-up of a single center cohort study (2007) (0)
The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials. (2011) (0)
Biclonal non-small cell lung cancer in disseminated tumor cells and tissue. (2012) (0)
Generation of autologous lymphokine-activated killer cells (LAK cells) against a differentiated thyroid cancer cell line (1989) (0)
Melanoma Group achievements (2012) (0)
Differential expression of chemokine receptors in primary central nervous system and extracerebral lymphomas (2005) (0)
Impact of interdisciplinary sarcoma board evaluation on treatment outcome of primary soft-tissue sarcoma patients. (2021) (0)
[Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]. (2020) (0)
WT1-Peptide Vaccination in Patients With Acute Myeloid Leukemia Shows High Immunogenicity Associated With Clinical Activity (2005) (0)
2776 Cancer testis antigen Cyclin A1 is broadly expressed in ovarian cancer and associated with prolonged time to progression after platinum-based chemotherapy (2015) (0)
Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. (2016) (0)
Expression and release of IL-2 receptor alpa- and beta-chain (CD25 and p75) in human monocytes and macrophages (1992) (0)
Immune self-tuning in renal cell carcinoma patients. (2009) (0)
7142 Immune tuning in renal cell carcinoma patients (2009) (0)
Quantitative Analysis of Wilms’ Tumor Gene 1(WT1) Expression in Acute Lymphoblastic Leukemia (ALL) of Adults Reveals Lower WT1 Levels Than in Acute Myeloid Leukemias (AML) and Varying Expression Levels between Individual Patients among Different ALL Subgroups. (2005) (0)
Abstract 3875: Functional and molecular characterization of colon cancer stem cells in tumor heterogeneity and disease relapse using a 3D-model of patient-derived tumors (2014) (0)
Minimal residual disease in malignant melanoma after immunotherapy (1993) (0)
Distribution of T-cell-subfamilies in melanoma metastases after treatment with interferon (IFN)-α/Interleukin (IL)-2 (1997) (0)
Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients (2004) (0)
Incidence and initial characterization of circulating tumor cells in different cancer entities. (2010) (0)
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. (2014) (0)
Gene expression-based prediction of pazopanib efficacy in sarcoma. (2022) (0)
Phenotypic and functional characteristics of patient derived murine xenograft models. (2019) (0)
Long-term structured follow-up is essential after curative cancer treatment. (2014) (0)
173 INVITED Immunotherapy approaches to stage IV melanoma (2007) (0)
Analysis of Immunological and Clinical Response Kinetics to WT1 Peptide Vaccine in Patients with AML and MDS: Need for Supplementation of IWG Response Criteria?. (2007) (0)
Identification of a Nervous System Gene Expression Signature in Colon Cancer Stem Cells Reveals a Role for Neural Crest Regulators EGR2 and SOX2 in Tumorigenesis (2021) (0)
Correlation between PI3K/PTEN/AKT/mTOR pathway genetic variations and clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. (2012) (0)
Abstract 977: 3D-models of patient-derived colon tumors for the identification of genetic factors important in the regulation of cancer stem cells (2015) (0)
668P Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC) (2022) (0)
A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma (2007) (0)
Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML (2004) (0)
ANALYSIS OF THE T CELL RESPONSE TO MELANOMA-ASSOCIATED PEPTIDE EPITOPES IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF MELANOMA PATIENTS AND HEALTHY DONERS BY AN ELISPOT ASSAY (1996) (0)
Liquid Biopsy in Colorectal Cancer: Quo Vadis? Implementation of Liquid Biopsies in Routine Clinical Patient Care in Two German Comprehensive Cancer Centers (2022) (0)
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany (2021) (0)
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors. (2018) (0)
Abstract 1674: Correlation of the mutational pattern and gene expression data of patient-derived Non-Hodgkin lymphoma xenografts (PDX) with the response to targeted therapies (2020) (0)
Abstract P6-03-06: Androgen supplementation in patient derived xenografts in androgen receptor positive breast cancer to increase engraftment and growth rate (2019) (0)
12 Next generation sequencing (NGS) guided therapy prediction for the treatment of glioblastoma multiforme (GBM) (2014) (0)
Epidemiology, prevalence, and prognosis of multiple malignancies of a subpopulation of a large German cancer center. (2020) (0)
Chapter 9 MINIMAL RESIDUAL DISEASE IN MELANOMA (2005) (0)
RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials (2016) (0)
Detection of circulating tumor cells by RT-PCR as a prognostic factor for distant metastases and survival uveal melanoma (2006) (0)
T-cell receptor repertoire in melanoma tissue and response to immunotherapy (1993) (0)
Gene- and Immunotherapy in Oncology: Study concepts, endpoints and first results (2003) (0)
University of Groningen The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node- positive melanoma without the need for completion lymph node dissection Verver, (2020) (0)
Basal subtype of head and neck cancer to define response to EGFR inhibitor treatment. (2016) (0)
Analysis of neuroendocrine marker synaptophysin and stem-cell related marker CD133 on circulating tumor cells (CTC) in patients with metastatic non-small cellular lung cancer (NSCLC). (2012) (0)
Summary of trials involving high dose IL-2 in patients with advanced melanoma: 407 (1997) (0)
SURGICAL RESECTION OF RESIDUAL DISEASE FOLLOWING IL-2-BASED IMMUNOTHERAPY (1993) (0)
Comparison of the clinical interpretation of high-dimensional molecular data by two molecular tumor boards. (2020) (0)
SP-047: Against the motion (2015) (0)
Acknowledgement to Reviewers (2007) (0)
Contents · Inhalt / Editorial (2000) (0)
VIST - a Variant-Information Search Tool for precision oncology (2019) (0)
Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies (2013) (0)
Regional Adoptive Immunotherapy for Hepatic Metastasis (1990) (0)
Immune escape mechanisms in patients with AML receiving WT1 peptide vaccination (2008) (0)
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial (2012) (0)
A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high-grade non-Hodgkin's lymphoma and cardiac risk factors. (2004) (0)
1679P A comparative analysis of cancer NGS reporting practices between Europe and North America (2022) (0)
Abstract 2434: Identification of new treatment options for platinum-resistant head and neck cancer in a panel of broadly characterized patient-derived xenografts. (2013) (0)
Cytokine-Based Treatments for Advanced Melanoma (1997) (0)
Malignant melanoma--clinical development of peptide-based melanoma vaccines. (2006) (0)
Vaccination of Patients with Recurrent AML with WT1-Peptide Induces Clinical and Molecular Remissions as Well as Specific Memory and Effector T Cells in Peripheral Blood and Bone Marrow (2004) (0)
3093 Veliparib with carboplatin and paclitaxel: factors predictive of favorable outcomes in NSCLC (2015) (0)
Charité – Universitätsmedizin Berlin Campus Benjamin Franklin Aus Der medizinischen Klinik III Hämatologie, Onkologie und Transfusionsmedizin Direktor: Herr Prof. Dr. E. Thiel Recombinant Fusion proteins for Antibody-Directed-Enzyme- Prodrug-Therapy (ADEPT) in colon cancer Inaugural - Dissertatio (2008) (0)
Title Page / Contents / Imprint (2014) (0)
GM-CSF Can Modulate the Migratory Phenotype of Vaccine-Induced T Cells by Enhancing CXCR3 Expression (2005) (0)
targeted therapy for Stauffer's Syndrome in a patient with renal cell carcinoma : P208 (2010) (0)
Characteristics and survival in patients with metastasic uveal melanoma: Analysis of a referral center cohort. (2011) (0)
HIGH FREQUENCIES OF TUMOR-REACTIVE CD8+ T CELLS IN MELANOMA AND COLON CANCER PATIENTS (1999) (0)
Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer. (2018) (0)
Treatment of metastatic uveal melanoma (mUM) directed by a comprehensive molecular tumour analysis program (CMTA). (2018) (0)
Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients (2018) (0)
Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform (2023) (0)
Clinical impact of comprehensive versus targeted genomic analysis for precision oncology. (2019) (0)
Uveal metastases: clinical characteristics and therapy for 72 patients (2016) (0)
Molecular subtypes of head and neck cancer predict response to cetuximab treatment (2016) (0)
8th Annual Meeting of the German Working Group for Gene Therapy (DAG-GT e.V.) (2014) (0)
Pretreatment characteristics and early indicators of long-term efficacy of cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN). (2013) (0)
Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells? (2013) (0)
Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives (2016) (0)
Retrospective analysis of the treatment of metastatic uveal melanoma comparing systemic chemotherapy and transarterial chemoembolization. (2018) (0)
Brain metastases in non-small cell lung cancer patients at the time of first diagnosis: Therapy and outcome. (2010) (0)
Relationship between soluble tumor necrosisfactor (TNF) receptors and TNF? during immunotherapywith interleukin-2 and/or interferon ? (1994) (0)
Efficacy of transarterial chemoembolization (TACE) of liver metastases from uveal melanoma (2008) (0)
CetuGEX and cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): PK/PD results from the phase II RESGEX study. (2018) (0)
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7] (2021) (0)
EORTC Melanoma Group achievements (2012) (0)
Abstract 2841: Her2/neu expression as potential marker of regorafenib resistance in CRC (2018) (0)
Fear of prognosis? How anxiety, coping, and expected burden impact the decision to have cytogenetic assessment in uveal melanoma patients (2022) (0)
Immunosuppressive treatment in stroke and renal failure (0)
920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort (2020) (0)
Characteristics of cancer patients with a history of solid organ transplantation: Analysis of a patient cohort reporting to a large cancer center. (2019) (0)
Metastatic uveal melanoma: A liver disease or a systemic disease? (2012) (0)
1218PDPrecision medicine for the treatment of metastatic uveal melanoma: A pilot study (2017) (0)
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. (2009) (0)
Cyclic RGDfV-peptides inhibit colorectal tumor growth in a chemically induced rat model (2001) (0)
Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses. (2018) (0)
Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells. (2012) (0)
Original article Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma (2004) (0)
Abstract 2783: Establishment and characterization of patient-derived xenografts of head and neck tumors. (2013) (0)
Abstract 901: Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma (2014) (0)
Abstract 1069: New panel of patient derived lymphoma xenografts (PDX) for preclinical research and immune oncology (2019) (0)
Prognostic molecular factors in patients with gastric cancer stage UICC I without lymph-node involvement. (2014) (0)
Abstract 1715: Whole transcriptome analysis of patient-derived 3D in vitro and xenograft models of colon cancer identifies placental genes required for the survival of cancer stem cells (2016) (0)
10 mTOR inhibition with everolimus – a novel treatment option for head and neck cancer identified in a translational research study using patient-derived xenografts (2014) (0)
Abstract 821: Comprehensive genomic analysis of rare cancers: Results of the MASTER precision oncology trial of the German Cancer Consortium (2020) (0)
Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients—A Single-Center Analysis of 1294 Patients within the Last Decade (2023) (0)
IL-2 based immunotherapy and chemo immunotherapy in melanoma (1993) (0)
103 INVITED WT1 peptide vaccines in leukaemias and WT-1 expressing carcinomas (2007) (0)
Micrometastatic Melanoma Cell Accumulation in Sentinel Lymph Nodes Containing Dendritic + Long-Term Protective Effect of Mature DC-LAMP (2007) (0)
CCR6 Expression Levels in Colorectal Cancer are Strongly Associated With Liver Metastasis (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ulrich Keilholz?

Ulrich Keilholz is affiliated with the following schools:

Aarhus University
Humboldt University of Berlin
University of Nottingham
University of Oxford
University of Glasgow

Ulrich Keilholz's Academic­Influence.com Rankings

Why Is Ulrich Keilholz Influential?

Ulrich Keilholz's Published Works

Published Works

What Schools Are Affiliated With Ulrich Keilholz?

Ulrich Keilholz's AcademicInfluence.com Rankings